The Translational Breast Cancer Research Consortium was well represented at the 2015 SABCS.  Presentations included:

Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC 008 comprising a platinum in HER2-negative primary operable breast cancer; Abstract # P3-07-13

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017; Abstract # S3-06

A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma (TBCRC 037); Abstract # P3-05-14